Severe Acute Respiratory Syndrome Clinical Trial
Official title:
Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of Inpatients During the COVID-19 Outbreak: A Prospective Cohort Study
Oslo University Hospital has initiated an observational study on hospitalised patients with confirmed COVID-19, the infection caused by Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2).
Infectious disease is the single biggest cause of death worldwide. New infectious agents,
such as the SARS-CoV-2, require investigation to understand pathogen biology and pathogenesis
in the host. In order to develop a mechanistic understanding of disease processes, such that
risk factors for severe illness can be identified and treatments can be developed, it is
necessary to understand pathogen characteristics associated with virulence, the replication
dynamics and in-host evolution of the pathogen, the dynamics of the host response, the
pharmacology of antimicrobial or host directed therapies, the transmission dynamics, and
factors underlying individual susceptibility.
At Oslo University Hospital, an observational study on the newly discovered emerging SARS-
CoV-2, the coronavirus that causes COVID-19 infection has started. The study has been
approved by the Regional Ethics Committee, so that inclusion of confirmed COVID-19 cases
admitted at the hospital can start immediately including the first patients needing
hospitalisation. The plan is to include more hospitals in other parts of Norway, starting
with inclusion of Akershus University Hospital, Vestre Viken Drammen Hospital and Østfold
Hospital. The study is anticipated to provide much needed data on the course of the COVID-19
infection, as well as generating knowledge about the virus and its transmission.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
| Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
| Recruiting |
NCT04480333 -
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
|
Phase 1 | |
| Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
| Not yet recruiting |
NCT04386070 -
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
|
Phase 3 | |
| Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
| Withdrawn |
NCT00073086 -
Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)
|
N/A | |
| Active, not recruiting |
NCT04527432 -
COVID-19 Health Professional Impact Study
|
N/A | |
| Completed |
NCT00215826 -
Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers
|
Phase 2 | |
| Completed |
NCT04366934 -
Study of the Pathogenesis of Olfactory Disorders in COVID-19
|
||
| Completed |
NCT04402060 -
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04376684 -
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
|
Phase 2 | |
| Completed |
NCT04395144 -
COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss
|
N/A | |
| Completed |
NCT04357730 -
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
|
Phase 2 | |
| Completed |
NCT04425213 -
Obesity and Mortality of Critically Ill Patients With COVID-19
|
||
| Completed |
NCT04425863 -
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
|
||
| Completed |
NCT06287554 -
Effect of Early Implementation of Prone Positioning
|
||
| Completed |
NCT04328129 -
Household Transmission Investigation Study for COVID-19 in Tropical Regions
|
N/A | |
| Completed |
NCT04602351 -
Communication in ICU During COVID-19
|
||
| Completed |
NCT03225807 -
Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure
|